OptimizeRx Corp

Will Febbo has served as CEO since 2008 — an unusually long tenure for a public micro-cap company — and he is supported by CFO/COO Edward Stelmakh and Chief Commercial Officer Steve Silvestro. Febbo oversaw the early pivot from consumer coupons to enterprise pharma software, and the senior team has remained largely stable through the company's acquisitions and product expansions. This continuity is atypical in digital health and contributes to consistent execution across multiple product launches.

Pharmaceutical manufacturers pay to place messaging and workflow tools inside electronic health record systems. The core products are financial messaging (copay cards, vouchers, patient assistance information that appears when a doctor prescribes), clinical education (peer-reviewed content surfaced at the prescribing moment), and an AI-driven care-guidance module that matches patient data to therapy opportunities. Revenue is almost entirely U.S.-based and comes from brand marketing budgets rather than hospital IT spend.

Integration depth within existing EHR workflow is the primary differentiator. Rather than asking clinicians to open a separate portal or application, the OptimizeRx platform surfaces affordability and education content inside the e-prescribing and clinical-decision-support screens doctors already navigate. This embedded distribution model gives it a structural advantage over standalone physician-engagement platforms — it does not compete for clinician attention, it rides inside the tools clinicians are already required to use.

The company does not disclose exact revenue concentration, but its client roster includes many of the largest pharmaceutical manufacturers — publicly cited relationships include Novartis, Pfizer, and Lilly. Because the platform provides broad EHR-integrated distribution rather than drug-specific solutions, a single manufacturer typically uses it across multiple brands and therapy areas, which diversifies the revenue relationship even where client count is concentrated.

The September 2023 Medisafe acquisition represents a strategic expansion from the point of care into the post-prescription patient journey. Medisafe operates a medication-adherence app with approximately 10 million registered patients, and the deal allows OptimizeRx to connect brand messaging in the EHR to ongoing patient engagement after the script is written. This creates a closed-loop architecture: a pharma brand can surface copay information at prescribing, then deliver adherence support and refill reminders directly to the patient's phone — all within OptimizeRx's platform, none of it requiring the clinician to change behavior.

OptimizeRx has established official integration partnerships with the dominant EHR vendors, including Epic and Cerner, as well as with e-prescribing networks that route prescriptions between doctors and pharmacies. These integrations are embedded at the application-programming-interface level and inside specific workflow screens, which means OptimizeRx content appears natively rather than as a pop-up or overlay. The company does not own or operate an EHR itself — it remains a neutral message-delivery layer that can work across competing EHR platforms.

OptimizeRx is publicly traded (NASDAQ: OPRX) and generates annual revenues in the range of $60–$80 million as of the most recent fiscal periods, with gross margins typical of a software platform — above 60%. The company traded at a market capitalization near $200 million in early 2024 and has historically run close to breakeven while investing in platform expansion. The Medisafe acquisition added scale and a consumer-facing asset, but introduced near-term integration costs that pressure operating margins.